Accrued Expense	9 Months Ended
Sep. 30, 2020
Accrued Expense
Accrued Expense	6. Accrued Expense As of September 30, 2020, current liabilities included accrued expenses of $0.7 million, comprised primarily of expenses related to the Company's clinical trial for prexigebersen in AML of $0.3 million, accrued employee vacation and bonus expenses of $0.3 million and other accrued expenses of $0.1 million. As of December 31, 2019, current liabilities included accrued expenses of $0.7 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, clinical and preclinical expenses of $0.2 million and other accrued expenses of $0.1 million.

Accrued Expense

9 Months Ended

Sep. 30, 2020

6. Accrued Expense

As of September 30, 2020, current liabilities included accrued expenses of $0.7 million, comprised primarily of expenses related to the Company's clinical trial for prexigebersen in AML of $0.3 million, accrued employee vacation and bonus expenses of $0.3 million and other accrued expenses of $0.1 million. As of December 31, 2019, current liabilities included accrued expenses of $0.7 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, clinical and preclinical expenses of $0.2 million and other accrued expenses of $0.1 million.